Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Targeted Anti-cancer Therapies (TAT) conference roundup

Share :
Published: 22 Apr 2014
Views: 2554
Rating:
Save
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

Prof Gordon McVie of ecancer and European Institute of Oncology, Milan, Italy gives a roundup of the 12th International Congress on Targeted Anti-cancer Therapies (TAT) conference.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024
Multiple myeloma in a resource constrained setting
Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda
Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )
22 Feb 2024
Updates on lung cancer from WCLC and ESMO 2023
Dr Luis Raez - Memorial Cancer Institute, Miami, USA
Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
31 Jan 2024
Systemic anti-cancer performance matrix
Prof Richard Sullivan, Kari Leung and Megan McLeod
Systemic anti-cancer performance matrix ( Prof Richard Sullivan, Kari Leung and Megan McLeod )
23 Nov 2022
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan
Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Sep 2022
Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly...
Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands
Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly improved PFS for advanced melanoma ( Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )
10 Sep 2022
ASCO Direct Highlights 2022: lung cancer highlights
Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA
ASCO Direct Highlights 2022: lung cancer highlights ( Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA )
9 Jul 2022
High-dose ifosfamide standard of care for recurrent and primary refractory...
Dr Martin McCabe - University of Manchester, Manchester, England
High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )
5 Jun 2022
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
5 Jun 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation